Trials / Conditions / Myelofibrosis (MF)

Myelofibrosis (MF)

25 registered clinical trials studyying Myelofibrosis (MF) — 13 currently recruiting.

Status	Trial	Sponsor	Phase
Not Yet Recruiting	Comparing Momelotinib and Ruxolitinib in People With Untreated Myelofibrosis and Low Blood Cell Counts NCT07498205	SWOG Cancer Research Network	Phase 4
Not Yet Recruiting	TACrolimus Targeted Immunosuppression Cessation in ALlogeneic HCT NCT07302776	Stanford University	Phase 1
Not Yet Recruiting	Study of ZE74-0282 for Patients With JAK2 V617F Positive Blood Cancers NCT07529951	Eilean Therapeutics	Phase 1
Recruiting	A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative Neoplasms NCT07469891	Prelude Therapeutics	Phase 1
Not Yet Recruiting	Gecacitinib Pre-, During- and Post-HSCT for Patients With Primary or Secondary Myelofibrosis NCT07471503	Institute of Hematology & Blood Diseases Hospital, China	Phase 2
Not Yet Recruiting	Pacritinib For Bone Marrow Fibrosis In Patients With Myelofibrosis Who Have Thrombocytopenia NCT07394153	Grupo Español de Enfermedades Mieloproliferativas Crónicas PH Negativas	Phase 2
Not Yet Recruiting	Momelotinib Effectiveness in Myelofibrosis NCT07249606	Gruppo Italiano Malattie EMatologiche dell'Adulto	—
Recruiting	Phase I/II Clinical Trial of Axatilimab, a CSF1R Monoclonal Antibody, in Combination With Ruxolitinib as Thera NCT07128381	M.D. Anderson Cancer Center	Phase 1 / Phase 2
Recruiting	A Study of Roginolisib in Combination With Ruxolitinib in Patients With Myelofibrosis (MF) Who Are Unresponsiv NCT06887803	iOnctura	Phase 1 / Phase 2
Recruiting	MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People NCT07362225	MPN Research Foundation	—
Not Yet Recruiting	Combination of Tagraxofusp with Pacritinib in Patients with Intermediate-1 or Higher Myelofibrosis, Who Have H NCT06414681	University of Kansas Medical Center	EARLY_Phase 1
Recruiting	MethoTRExATE in MyelOpRolifErative Neoplasms (TREATMORE) Trial NCT06541249	Icahn School of Medicine at Mount Sinai	Phase 2
Recruiting	A New Diagnostic Algorithm to Non-invasively Track Fibrotic Changes in Myeloproliferative Neoplasms Based on C NCT07419178	Azienda Ospedaliero-Universitaria di Parma	N/A
Active Not Recruiting	Unraveling the Role of Extracellular Vesicles-driven Senescence in Myeloproliferative Neoplasms NCT06798805	IRCCS Azienda Ospedaliero-Universitaria di Bologna	—
Completed	Safety of Flonoltinib Maleate Tablets for the Treatment of Patients With Myeloproliferative NCT05153343	Chengdu Zenitar Biomedical Technology Co., Ltd	Phase 1 / Phase 2
Unknown	Study of Flonoltinib Maleate Tablets in the Treatment of Proliferative Bone Marrow Tumors NCT05115344	Chengdu Zenitar Biomedical Technology Co., Ltd	Phase 1
Terminated	Safety and Tolerability Study of Mivebresib Tablet Alone or in Combination With Ruxolitinib Tablet or Navitocl NCT04480086	AbbVie	Phase 1
Active Not Recruiting	Safety and Tolerability Study of Oral ABBV-744 Tablet Alone or in Combination With Oral Ruxolitinib Tablet or NCT04454658	AbbVie	Phase 1
Completed	Study of Oral Navitoclax Tablet In Combination With Oral Ruxolitinib Tablet When Compared With Oral Ruxolitini NCT04472598	AbbVie	Phase 3
Active Not Recruiting	Study of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet Versus Best Available Therapy to A NCT04468984	AbbVie	Phase 3
Completed	A Study Evaluating Tolerability and Efficacy of Navitoclax Alone or in Combination With Ruxolitinib in Partici NCT03222609	AbbVie	Phase 2
Completed	Screening for Asymptomatic Portal Vein Thrombosis and Portal Hypertension in Patients With Philadelphia Negati NCT01816256	University Health Network, Toronto	N/A
Suspended	Study of KB004 in Subjects With Hematologic Malignancies (Myelodysplastic Syndrome, MDS, Myelofibrosis, MF) NCT01211691	Humanigen, Inc.	Phase 1 / Phase 2
Completed	Traditional Chinese Medicine in the Supportive Management of Anaemic and Cytopenic (Leukopenia, Thrombocytopen NCT01224496	Singapore General Hospital	Phase 1 / Phase 2